NapaJen Logo.jpg
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
October 08, 2020 07:35 ET | NapaJen
NJA-730 is an Anti-CD-40 Oligonucleotide Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease (aGvHD) Treatment Shown to be Safe and Well-Tolerated...
22157.jpg
Global RNAi Technologies, Markets & Companies Report 2020 with Profiles of 167 Companies Along with 229 Collaborations
September 21, 2020 04:13 ET | Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. The report...
22157.jpg
World RNAi Market 2020-2025: Oncology is Expected to Hold Significant Market Share in the Therapeutics Type Area
August 31, 2020 05:44 ET | Research and Markets
Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The...
vynzresearch_logo.png
Global Agricultural Biotechnology Market was Valued at USD 33.8 billion by 2024, Observing a CAGR of 10.9% during 2019–2024: VynZ Research
December 17, 2019 13:35 ET | VynZ Research
NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- The global agricultural biotechnology market was valued at USD 33.8 billion in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period....
NapaJen Logo.jpg
NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
November 15, 2018 07:35 ET | NapaJen
NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...
MULTI_LOGO_SWRPT.png
Streetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
December 21, 2017 08:00 ET | Streetwise Reports Llc
SAN FRANCISCO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. Included in this...
MDRNA Adds June D. Ameen to Management Team as Vice President, Corporate Development
September 08, 2009 08:00 ET | MDRNA, Inc.
BOTHELL, WA--(Marketwire - September 8, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that June D. Ameen, RN, MBA, will join the Company as Vice President, Corporate Development reporting to the...
MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
August 11, 2009 09:15 ET | MDRNA, Inc.
BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number...